

ABOUT THE TEST FoundationOne®Liquid is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating tumor DNA.

PATIENT

DISEASE **Lung cancer (NOS)**
 NAME
 DATE OF BIRTH
 SEX **Male**
 MEDICAL RECORD # **Not given**

PHYSICIAN

ORDERING PHYSICIAN
 MEDICAL FACILITY
 ADDITIONAL RECIPIENT **None**
 MEDICAL FACILITY ID
 PATHOLOGIST **Not Provided**

SPECIMEN

SPECIMEN ID
 SPECIMEN TYPE **Blood**
 DATE OF COLLECTION
 SPECIMEN RECEIVED
 MEDIAN EXON COVERAGE

Biomarker Findings

MSI Status **Undetermined.**

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

ATM I1469M
STK11 G276fs*11

5 Therapies with Clinical Benefit
 0 Therapies with Lack of Response

19 Clinical Trials

BIOMARKER FINDINGS

ACTIONABILITY


MSI Status Undetermined

GENOMIC FINDINGS	MAF %	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
ATM - I1469M	0.26%	None	Drug 1 Drug 2 Drug 3
10 Trials see p. 7			
STK11 - G276fs*11	0.35%	None	Drug 4 Drug 5
10 Trials see p. 9			

NOTE Genomic alterations detected may be associated with activity of certain FDA-approved drugs; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. In the appropriate clinical context, germline testing of *APC, BRCA1, BRCA2, CDH1, NF1, PALB2, RB1, RET, STK11*, and *TP53* is recommended.

Mutant Allele Frequency is not applicable for copy number amplifications or rearrangements.

Mutant Allele Frequency
Percentage (MAF%)



HISTORIC PATIENT FINDINGS		TEST 1 MAF%
ATM	● I1469M	0.26%
STK11	● G276fs*11	0.35%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid or FoundationOne® tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

GENE
ATM

ALTERATION
I1469M

POTENTIAL TREATMENT STRATEGIES

Loss of functional ATM results in a defective DNA damage response and homologous recombination-mediated DNA repair, and may predict sensitivity to PARP inhibitors¹ such as xxxxxxxx, xxxxxxxx, and xxxxxxxx. Several preclinical studies have shown that loss of functional ATM confers moderate sensitivity to PARP inhibitors²⁻⁶, with some studies reporting increased sensitivity specifically in cells with loss of both ATM and TP53⁷⁻⁸; one preclinical study reported that ATM depletion did not increase sensitivity to PARP inhibitors⁹. In a Phase 2 trial, 4/5 patients with ATM-mutated castration-resistant prostate cancer benefited from xxxxxxxx treatment¹⁰. In a Phase 2 study of patients with gastric cancer, the combination of xxxxxxxx with xxxxxxxx

resulted in improved overall survival versus xxxxxxxx alone, both in the overall patient population and the patient population with low ATM protein expression¹¹. Preclinical experiments also indicate that loss of ATM causes dependency on DNA-PKcs in cancer cells; DNA-PKcs inhibitors promoted apoptosis in ATM-deficient cells, and were active in a lymphoma mouse model lacking ATM activity, suggesting a potential therapeutic strategy for tumors with inactivating ATM mutations¹². It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.

FREQUENCY & PROGNOSIS

ATM mutations have been reported in 8-11% of lung adenocarcinomas¹³⁻¹⁵ and 5% of lung squamous cell carcinomas (SCCs)¹⁶. Expression of ATM protein has been reported to be significantly higher in non-small cell lung carcinoma samples than in normal tissues¹⁷. In one study, higher ATM protein levels in

lung SCC, but not in lung adenocarcinoma, significantly correlated with shorter disease-free and overall survival of patients treated with xxxxxxxx¹⁸.

FINDING SUMMARY

ATM encodes the protein ataxia telangiectasia mutated, which is a serine/threonine protein kinase that plays a key role in the DNA damage response¹⁹. Loss of functional ATM promotes tumorigenesis²⁰ and mutations in ATM underlie the rare autosomal recessive inherited disorder ataxia-telangiectasia that is characterized by genomic instability, sensitivity to DNA-damaging agents, and increased risk of developing cancer¹⁹. Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

GENE
STK11

ALTERATION
G276fs*11

POTENTIAL TREATMENT STRATEGIES

Increased mTOR signaling is present in LKB1-deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations²¹⁻²⁵. The mTOR inhibitors xxxxxxxx and xxxxxxxx are FDA approved for the treatment of other tumor types, and are being investigated in clinical trials for several indications²⁶⁻²⁹. A PJS patient with pancreatic cancer and an STK11 mutation experienced a partial response to the mTOR inhibitor xxxxxxxx³⁰. Loss of STK11 also leads to activation of the downstream kinase SRC, suggesting that inhibitors such as xxxxxxxx or xxxxxxxx may be relevant for the treatment of LKB1-deficient tumors³¹.

cancer (NSCLC) (15-35%), with alterations more prevalent in lung adenocarcinomas (13-34%) than in lung squamous cell carcinoma (2-19%)^{15-16,22,32-35}. In the TCGA datasets, STK11 homozygous deletion was observed in 1% of lung adenocarcinoma cases³³ and was not observed in any of 178 lung squamous cell carcinoma cases¹⁶. Strongly decreased or absent expression of LKB1 correlated with inferior outcome in patients with NSCLC treated with xxxxxxxx; expression of LKB1 was not prognostic in patients treated with chemotherapy without xxxxxxxx³⁶. STK11 mutations in NSCLC often co-occur with activating KRAS mutations³⁴⁻³⁵. In transgenic mouse models, animals expressing mutant KRAS developed lung adenocarcinomas, whereas the KRAS-mutant/LKB1-deficient mice developed an expanded histological spectrum of tumors that included large cell and squamous cell carcinomas²².

changes in cellular energy levels²¹. LKB1 acts as a tumor suppressor in cancer, as loss of function promotes proliferation and tumorigenesis^{31,37}. Functional disruption of the STK11 kinase domain (amino acids 49-309) or STRAD binding domain (amino acids 320-343) through mutation or loss, such as observed here, is predicted to be inactivating³⁸⁻⁴⁹. Germline mutations in STK11 underlie Peutz-Jeghers syndrome (PJS), a rare autosomal dominant disorder associated with a predisposition for tumor formation⁵⁰. This disorder has an estimated frequency between 1:29,000 and 1:120,000, although reported rates in the literature vary greatly. Although gastrointestinal tumors are the most common malignancies associated with PJS, patients also exhibit an 18-fold increased risk of developing other epithelial cancers⁵⁰⁻⁵², and individuals with this syndrome have a 30-50% risk of developing breast cancer^{50,52}. Given the association with PJS, in the appropriate clinical context testing for the presence of germline mutations in STK11 is recommended.

FINDING SUMMARY

The serine/threonine kinase STK11 (also called LKB1) activates AMPK and negatively regulates the mTOR pathway in response to

FREQUENCY & PROGNOSIS

Several clinical studies have found STK11 mutation to be common in non-small cell lung

DRUG 1

Assay findings association

STK11
G276fs*11

APPROVED INDICATIONS

xxxxxxx is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors and well-differentiated nonfunctional neuroendocrine tumors of the lung or gastrointestinal tract; and, in association with tuberous sclerosis complex (TSC), renal angiomyolipoma and subependymal giant cell astrocytoma. xxxxxxxxxx is also approved to treat hormone receptor-positive, HER2-negative advanced breast cancer in combination with xxxxxxxx following prior therapy with xxxxxxxx or xxxxxxxx, as well as in combination with the multikinase inhibitor xxxxxxxx to treat advanced RCC following prior antiangiogenic therapy.

GENE A

Increased mTOR signaling is present in LKB1-deficient tumors^{21-22 23,53 25}; therefore, therapies targeting mTOR may be relevant for tumors with STK11 alterations²¹. xxxxxxx elicited clinical responses lasting >6 months in 2 patients with pancreatic cancer^{30,54} and 1 patient with atypical pituitary adenoma⁵⁵, all of whom harbored STK11 alterations in their tumors.

SUPPORTING DATA

A trial of xxxxxxx as a monotherapy in non-small cell lung cancer (NSCLC) showed modest activity⁵⁶, but a Phase 2 study of xxxxxxx in combination with xxxxxxx did not show any added benefit of xxxxxxx in an unselected population⁵⁷. A Phase 1 study evaluated the addition of xxxxxxx to xxxxxxx and xxxxxxx +/-xxxxxxx in advanced NSCLC and found the combinations produced 1 complete response and 10 partial responses (n=52), although treatments were not well tolerated⁵⁸. A Phase 1 study in patients with advanced NSCLC of the combination of xxxxxxx and xxxxxxx reported 9 objective responses and 28 patients experiencing stable disease (n=74), but a Phase 2 study found the combination inefficacious at tolerated doses⁵⁹⁻⁶⁰. A trial of combination treatment with xxxxxxx and xxxxxxx that included 2 patients with lung adenocarcinoma reported a partial response in one patient and stable disease in the other, with both patients experiencing progression-free survival of more than 4 months⁶¹. A Phase 1b trial of a combination of xxxxxxx and xxxxxxx in patients with solid tumors reported frequent adverse events and the study was unable to identify a recommended Phase 2 dose and schedule for the combination⁶².

Niraparib

Assay findings association

ATM
I1469M

APPROVED INDICATIONS

The PARP inhibitor xxxxxxx is FDA approved for the maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer who are in a complete or partial response to xxxxxxx chemotherapy.

GENE A

ATM inactivation may predict sensitivity to PARP inhibitors. Clinical benefit of various PARP inhibitors has been associated with ATM alterations in prostate cancer¹⁰,

gastric cancer¹¹, and papillary renal cell carcinoma⁶³. It is not known whether this therapeutic approach would be relevant in the context of alterations that have not been fully characterized, as seen here.

SUPPORTING DATA

In a Phase 1 study of niraparib treatment for patients with solid tumors, 2/2 patients with non-small cell lung cancer achieved stable disease; 1/2 patients harbored a BRCA2 mutation⁶⁴.

Drug 2

Assay findings association

ATM
I1469M

APPROVED INDICATIONS

The PARP inhibitor xxxxxxxx is FDA approved to treat advanced ovarian cancer with deleterious or suspected deleterious germline BRCA mutations after 3 or more prior lines of chemotherapy and for maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. xxxxxxxx is also approved to treat patients with HER2-negative metastatic breast cancer and deleterious or suspected deleterious germline BRCA mutations who have been previously treated with chemotherapy; patients with hormone receptor-positive breast cancer should have been previously treated with, or considered inappropriate for, endocrine therapy.

GENE A

Loss or inactivation of ATM may predict sensitivity to xxxxxxx^{2,10}. In a Phase 2 study of patients with gastric cancer, the combination of xxxxxxx with xxxxxxx resulted in improved overall survival versus xxxxxxx

alone, both in the overall patient population and the patient population with low ATM protein expression¹¹. Furthermore, 4/5 patients with ATM-mutated castration-resistant prostate cancer were reported to benefit from xxxxxxx treatment¹⁰ and a patient with ATM-mutated papillary renal cell carcinoma benefited from PARP inhibitor xxxxxxx for 7 months⁶³. It is not known whether this therapeutic approach would be relevant in the context of alterations that have not been fully characterized, as seen here.

SUPPORTING DATA

In a Phase 2 study, the addition of xxxxxxx to xxxxxxx did not significantly increase either median PFS (10.9 vs. 12.8 months; HR 0.75, p=0.12) or median OS (23.1 vs. 23.3 months; HR 1.22, p=0.346) in patients with EGFR-mutant NSCLC, unselected for other mutations; the ORR for patients treated with the combination (71%, 60/84) was similar to that of those treated with single-agent xxxxxxx (68%, 61/90)⁶⁵.

DRUG 3

Assay findings association

ATM
I1469M

APPROVED INDICATIONS

The PARP inhibitor xxxxxxx is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations who have been previously treated with two or more chemotherapies. xxxxxxx is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer who are in complete or partial response to xxxxxxx chemotherapy.

GENE A

ATM inactivation may predict sensitivity to PARP inhibitors. Clinical benefit of various PARP inhibitors has been associated with ATM alterations in prostate cancer¹⁰, gastric cancer¹¹, and papillary renal cell carcinoma⁶³. It is not known whether this therapeutic approach would be relevant in the context of alterations that have not been fully characterized, as seen here.

SUPPORTING DATA

Clinical data on the efficacy of xxxxxxx for the treatment of non-small cell lung carcinoma are limited (PubMed, Sep 2018). Rucaparib has primarily been evaluated in the context of ovarian carcinoma, breast carcinoma, pancreatic carcinoma, and melanoma. In a Phase 2 study of xxxxxxx for recurrent, platinum-sensitive ovarian, peritoneal, or fallopian tube carcinoma, median progression-free survival was significantly longer in patients with BRCA1/2 mutations (12.8 months) or high loss of heterozygosity (LOH; 5.7 months) compared to patients with low LOH (5.2 months). Objective responses were observed for 80% (32/40) of patients with BRCA1/2

mutations, for 29% (24/82) with high LOH, and for 10% (7/10) with low LOH⁶⁶. In heavily pretreated patients with a germline BRCA1/2 mutation who had received 2-4 prior chemotherapy treatments and had a progression free interval of greater than 6 months, 65% (17/26) of patients achieved an objective response with xxxxxxx treatment⁶⁷. In a Phase 2 study evaluating xxxxxxx for patients with advanced breast or ovarian cancer and germline BRCA1/2 mutations, disease control was observed in 92% (12/13) of patients with ovarian cancer treated with oral xxxxxxx dosed continuously, but no objective responses were reported in breast cancer patients (n=23). However, 39% (9/23) of evaluable patients with breast cancer achieved stable disease (SD) lasting 12 weeks or more⁶⁸. In a Phase 1 study of xxxxxxx treatment in patients with solid tumors, 3/4 patients with ovarian cancer and 1/1 patient with breast cancer given the recommended Phase 2 dose reported objective responses; all responders harbored BRCA1/2 mutations⁶⁹. A Phase 2 study of xxxxxxx treatment for patients with relapsed pancreatic cancer reported 1/19 complete response (CR), 2/19 partial response (PR; one unconfirmed) and 4/19 SD. Of the 19 patients treated in the study, 15 (79%) had a BRCA2 mutation⁷⁰. In a Phase 2 study of intravenous xxxxxxx in combination with xxxxxxx for patients with metastatic melanoma, 8/46 patients achieved a PR and 8/46 had SD⁷¹; a Phase 1 study reported 1 CR, 1 PR, and 4 SD lasting six months or longer in patients with metastatic melanoma⁷². A Phase 1 study of intravenous and oral xxxxxxx in combination with chemotherapy for the treatment of advanced solid tumors reported a disease control rate of 68.8% (53/77), including 1 CR and 9 PRs⁷³.

DRUG 4

Assay findings association

STK11
G276fs*11

APPROVED INDICATIONS

xxxxxxxxxx is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma.

GENE A

Increased mTOR signaling is present in LKB1-deficient tumors^{21-22 23,53 25}; therefore, therapies targeting mTOR may be relevant for tumors with STK11 alterations²¹.

SUPPORTING DATA

In a Phase 2 clinical trial in non-small cell lung cancer (NSCLC), front-line xxxxxxxxx monotherapy demonstrated some clinical benefit but failed to meet the trial's primary end point⁷⁴. In a Phase 1 trial of xxxxxxxxx and radiation in patients with NSCLC, of 8 evaluable patients, 3 exhibited a partial response and 2 exhibited stable disease⁷⁵.

Note: Genomic alterations detected may be associated with activity of certain FDA approved drugs, however the agents listed in this report may have little or no evidence in the patient's tumor type.



IMPORTANT Clinical trials are ordered by gene and prioritized in the following descending order: pediatric trial qualification → Geographical proximity → Later trial phase → Trial verification within last 2 months. While every effort is made to ensure the accuracy of

the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not meant to be a complete list of available trials and does not necessarily indicate that

the patient will meet clinical trial enrollment criteria. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov.

GENE
ATM

ALTERATION
I1469M

RATIONALE
Loss or inactivation of ATM may increase sensitivity to PARP inhibitors or inhibitors of DNA-PKcs. It is not known whether these

therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.

NCT02264678

PHASE 1/2

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.

TARGETS
ATR, PARP, PD-L1

LOCATIONS: California, New York, MARSEILLE Cedex 5 (France), Villejuif (France), Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), London (United Kingdom), Manchester (United Kingdom), Sutton (United Kingdom)

NCT02412371

PHASE 2

A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of xxxxxxxx in Combination With xxxxx/xxxxx-Based Chemoradiotherapy Followed by xxxxxxxx and xxxxxxxx/xxxxxxxxx Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)

TARGETS
PARP

LOCATIONS: California, Delaware, Illinois, Maryland, Massachusetts, New York, North Carolina, Rhode Island, Texas, Virginia

NCT02498613

SE 2

A Phase 2 Study of xxxxxxxx in Combination With xxxxxxxx in Advanced Solid Tumors

TARGET
PARP, VEGFRs

LOCATIONS: Vancouver (Canada), California, Connecticut, Florida, Michigan, Toronto (Canada), Tennessee, Texas, Virginia

NCT02154490

PHASE 2/3

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

TARGETS
PARP, CTLA-4, PD-1

LOCATIONS: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Hamilton (Canada), Ottawa (Canada), Toronto (Canada), Oregon, Pennsylvania, Rhode Island, Regina (Canada), South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

NCT02921919

PHASE 2

A Single-arm, Open-label, Multicenter, Extended Treatment, Safety Study In Patients Treated With xxxxxxxxxx

TARGETS
PARP

LOCATIONS: Edmonton (Canada), California, Florida, Indiana, Michigan, New Jersey, Hamilton (Canada), Montreal (Canada), Sutton (United Kingdom), Texas, Yaroslavl (Russian Federation), Budapest (Hungary), Chisinau (Moldova, Republic of), Moscow (Russian Federation), Saint-Petersburg (Russian Federation)

NCT02997176

PHASE 1

A Phase I Open-label Pharmacokinetics And Safety Study Of xxxxxxxxxx (mdv3800) In Patients With Advanced Solid Tumors And Normal Or Varying Degrees Of Hepatic Impairment

TARGETS
PARP

LOCATIONS: California, Florida, Massachusetts, Texas

NCT02079636
PHASE 1

A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

TARGETS
CDK4, CDK6, VEGFR2, PD-1, DNA-PK, PI3K, mTOR

LOCATIONS: Arkansas, California, Indiana, New Jersey, New Mexico, North Carolina, Tennessee, Madrid (Spain), Majadahonda (Spain), Sevilla (Spain)

NCT02693535
PHASE 2

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

TARGETS
VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, CDK4, CDK6, CSF1R, FLT3, KIT, PDGFRs, RET, mTOR, EGFR, ERBB3, ERBB2, BRAF, MEK, SMO, DDR2, RAF1, PARP, PD-1

LOCATIONS: Arizona, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Utah, Washington

NCT01012817
PHASE 1/2

A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-Ribose) Polymerase (PARP), and xxxxxxxx (TPT) in Patients With Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy

TARGETS
TOP1, PARP

LOCATIONS: Arizona, California, Florida, Illinois, Kansas, Minnesota, Pennsylvania

NCT02289690
PHASE 2

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of xxxxxxxx in Combination With xxxxxxxx and xxxxxxxx as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

TARGETS
PARP, TOP2

LOCATIONS: Arizona, Colorado, Georgia, Illinois, North Carolina, Ohio, Pennsylvania, Texas, Albury (Australia), Douglas (Australia), Frankston (Australia), Wollongong (Australia), Brussels (Belgium), Edegem (Belgium), Liege (Belgium), Mons (Belgium), Namur (Belgium), Calgary (Canada), Edmonton (Canada), Hamilton (Canada), Montreal (Canada), Nova Ves Pod Plesi (Czech Republic), Novy Jicin (Czech Republic), Ostrava (Czech Republic), Pardubice (Czech Republic), Nova Ves Pod Plesi (Czechia), Novy Jicin (Czechia), Ostrava (Czechia), Pardubice (Czechia), Creteil (France), Le Mans (France), Limoges (France), Limousin (France), Budapest (Hungary), Debrecen (Hungary), Farkasgyepu Kulterulet (Hungary), Győr (Hungary), Matrahaza (Hungary), Szekesfehervar (Hungary), Szolnok (Hungary), Szombathely (Hungary), Busan (Korea, Republic of), Chungcheongbuk-do (Korea, Republic of), Jeonnam (Korea, Republic of), Seoul (Korea, Republic of), Groningen (Netherlands), Harderwijk (Netherlands), Heerlen (Netherlands), Nijmegen (Netherlands), Rotterdam (Netherlands), Utrecht (Netherlands), Zwolle (Netherlands), Belgorod (Russian Federation), Ekaterinburg (Russian Federation), Moscow (Russian Federation), Murmansk (Russian Federation), Saint Petersburg (Russian Federation), Saransk (Russian Federation), Volgograd (Russian Federation), Barcelona (Spain), Madrid (Spain), Madrid (España) (Spain), Majadahonda, Madrid (Spain)

GENE
STK11

ALTERATION
G276fs*11

RATIONALE
Increased mTOR signaling is present in LKB1-deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations. In addition, analysis in lung

tumors indicate that loss of LKB1 function may result in SRC activation, suggesting inhibitors of the SRC kinases may be clinically beneficial when LKB1 is inactive.

NCT02750514

PHASE 2

A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

TARGETS
CTLA-4, LAG-3, ABL, DDR2, KIT, PDGFRs, SRC, PD-1

LOCATIONS: Edmonton (Canada), California, Colorado, Connecticut, District of Columbia, Georgia, London (United Kingdom), Kansas, Maryland, Massachusetts, Michigan, Missouri, Nevada, New York, North Carolina, Ohio, Hamilton (Canada), Ottawa (Canada), Oregon, Pennsylvania, Tennessee, Texas, Utah, Clayton (Australia), Virginia, Washington, Salzburg (Austria), Copenhagen (Denmark), Paris (France), Toulouse (France), Toulouse Cedex 9 (France), Villejuif (France), Villejuif Cedex (France), Milan (Italy), Milano (Italy), Rozzano (Italy), Amsterdam (Netherlands), Oslo (Norway), Madrid (Spain), Pamplona (Spain), Stockholm (Sweden), Lausanne (Switzerland)

NCT01920061

PHASE 1

A Phase 1b Open-label Three-arm Multi-center Study To Assess The Safety And Tolerability Of xxxxxxxxxx (pi3k/Mtor Inhibitor) In Combination With Other Anti-tumor Agents

TARGETS
PI3K-alpha, PI3K-gamma, mTORC1, mTORC2, EGFR, ERBB2, ERBB4

LOCATIONS: Alabama, Vancouver (Canada), California, Colorado, Massachusetts, Michigan, Toronto (Canada), Pennsylvania, South Carolina, Milan (Italy), Roma (Italy), Barcelona (Spain), Madrid (Spain), London (United Kingdom), Oxford (United Kingdom)

NCT02079636

PHASE 1

A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

TARGETS
CDK4, CDK6, VEGFR2, PD-1, DNA-PK, PI3K, mTOR

LOCATIONS: Arkansas, California, Indiana, New Jersey, New Mexico, North Carolina, Tennessee, Madrid (Spain), Majadahonda (Spain), Sevilla (Spain)

NCT01737502

PHASE 1/2

A Phase I-II Trial of Combined PKC α and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options

TARGETS
mTOR

LOCATIONS: Arizona

NCT02719691

PHASE 1

A Phase 1b Study of the Combination of xxxxxxxxxx (Dual TORC1/2 Inhibitor) and xxxxxxxxxx (Aurora A Inhibitor, xxxxxxxx) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)

TARGETS
mTORC2, mTORC1, Aurora kinase A

LOCATIONS: Colorado

NCT02576444

PHASE 2

A Phase II Study of the PARP Inhibitor xxxxxxxx (AZD2281) Alone and in Combination With xxxxxxxx, xxxxxxxx, or xxxxxxxxxx in Advanced Solid Tumors

TARGETS
PARP, AKTs, WEE1, mTORC1, mTORC2

LOCATIONS: Connecticut, Massachusetts, Tennessee

<p>NCT01884285</p>	<p>PHASE 1</p>
<p>A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of xxxxxxxx in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated/ Amplified Advanced Solid Malignancies as Monotherapy and in Combination With xxxxxxxxxx or xxxxxxxxxx</p>	<p>TARGETS PI3K-beta, CYP17, mTORC1, mTORC2</p>
<p>LOCATIONS: Massachusetts, Michigan, New York, Toronto (Canada), Washington, Wisconsin, Barcelona (Spain), London (United Kingdom), Manchester (United Kingdom), Sutton (United Kingdom)</p>	
<p>NCT01529593</p>	<p>SE 1</p>
<p>Phase I Study of xxxxxxxx in Combination With xxxxxxxx in Patients With Advanced Cancers</p>	<p>TARGET AMPK, mTOR</p>
<p>LOCATIONS: Texas</p>	
<p>NCT01552434</p>	<p>PHASE 1</p>
<p>A Phase I Trial of xxxxxxxxxx, xxxxxxxxxx Alone and in Combination With xxxxxxxxxx or xxxxxxxxxx in Patients With Advanced Malignancy and Other Indications</p>	<p>TARGETS VEGFA, HDAC, mTOR, EGFR</p>
<p>LOCATIONS: Texas</p>	
<p>NCT01582191</p>	<p>PHASE 1</p>
<p>A Phase 1 Trial of xxxxxxxx (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With xxxxxxxxxx (an mTOR Inhibitor) in Advanced Cancer</p>	<p>TARGETS mTOR, EGFR, RET, SRC, VEGFRs</p>
<p>LOCATIONS: Texas</p>	

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ATM
Y1470C

CHEK2
R346C

SAMPLE

FoundationOne Liquid interrogates the complete exonic sequence of 35 genes, introns of 7 genes involved in rearrangements, and select exons of an additional 35 genes. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/ DELETIONS, AND COPY NUMBER ALTERATIONS

APC	AR	ATM	BRCA1	BRCA2	CCND1	CD274 (PD-1)	CDH1	CDK4
CDK6	CDK12	CDKN2A	CHEK2	CRKL	EGFR	ERBB2	ERRF1	FGFR1
FGFR2	FOXL2	KRAS	MDM2	MET	MYC	MYCN	NF1	PALB2
PDCD1LG2 (PD-L2)	PTEN	PTPN11	RB1	SMO	STK11	TP53	VEGFA	

DNA GENE LIST: SELECT EXONIC SEQUENCE OF THE DETECTION OF BASE SUBSTITUTIONS, INSERTIONS/ DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1 Exons 4-9	AKT1 Exon 3	ALK Exons 20-29	ARAF Exons 4, 5, 7, 11, 13, 15, 16	BRAF Exons 11-18	BTK Exons 2, 15	CTNNB1 Exon 3	DDR2 Exons 5, 17, 18	ESR1 Exons 4-8
EZH2 Exons 4, 16, 18	FGFR3 Exons 7, 9, 14	FLT3 Exons 14, 15, 20	GNA11 Exons 4, 5	GNAQ Exons 4, 5	GNAS Exons 1, 8	HRAS Exons 2, 3	IDH1 Exon 4	IDH2 Exon 4
JAK2 Exon 14	JAK3 Exons 5, 11-13, 15, 16	KIT Exons 8, 9, 11-13, 17	MAP2K1 (MEK1) Exons 2, 3	MAP2K2 (MEK2) Exons 2-4, 6, 7	MPL Exon 10	MTOR Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56	MYD88 Exon 4	NPM1 Exons 4-6, 8, 10
NRAS Exons 2, 3	PDGFRA Exons 12, 18	PDGFRB Exons 12-21, 23	PIK3CA Exons 2, 3, 5-8, 10, 14, 19, 21	RAF1 Exons 3-7, 10, 14, 15, 17	RET Exons 11, 13-16	ROS1 Exons 36-38, 40	TERT (Promoter only)	

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	EGFR	FGFR2	FGFR3	PDGFRA	RET	ROS1
-----	------	-------	-------	--------	-----	------

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite Status (MS)

The median exon coverage for this sample is 5,176x

PERFORMANCE SPECIFICATIONS

	Mutant Allele Frequency (MAF) / Tumor Fraction‡	Sensitivity*	Positive Predictive Value (PPV)*
Base Substitutions	>0.5%	99.9% (99.7%-99.9%)	100% (99.9%-100%)
	0.25%-0.5%	95.8% (94.5%-96.9%)	99.8% (99.3%-99.9%)
	<0.25%	68.4% (65.7%-70.9%)	96.1% (94.8%-97.1%)
Insertions/Deletions†	>0.5%	99.7% (98.7%-99.9%)	100% (99.3%-100%)
	0.25%-0.5%	87.7% (81.1%-92.2%)	98.8% (95.4%-99.8%)
	<0.25%	60.5% (52.7%-67.7%)	96.8% (92.3%-98.8%)
Rearrangements**	>0.5%	100% (85.9%-100%)	100% (85.9%-100%)
	0.25%-0.5%	89.4% (65.5%-98.2%)	100% (77.1%-100%)
	<0.25%	68.4% (43.5%-86.4%)	100% (71.7%-100%)
Copy Number Amplifications§	≥20%	95.3% (82.9%-99.2%)	97.6% (85.9%-99.9%)
	<20%	Varies depending on amplitude of CNA and ctDNA fraction	
MSI¶	>2.0%	92.0% (72.5%-98.6%)	100% (82.2%-100%)
Reproducibility (average concordance between replicates)			
97.7% inter-batch precision		95.9% intra-batch precision	

*95% confidence intervals. Sensitivity assessment for <0.25% bin restricted to alterations in the 0.125%-0.25% expected allele frequency range.

†Deletions up to 2kb and insertions up to 40bp are detected. Sensitivity is lower for indels in repetitive regions.

**Performance for gene fusions within targeted introns only. Sensitivity for gene fusions occurring outside targeted introns or in highly repetitive intronic sequence contexts is reduced.

‡Sensitivity for MSI and copy number amplifications was determined using contrived samples with tumor fraction >20%. Most clinical samples will have less than 20% tumor fraction.

§Copy-number ≥8.

¶Microsatellite status, which is a measure of microsatellite instability (MSI), is determined by assessing indel characteristics at a subset of homopolymer repeat loci covered by the assay. Microsatellite status is assayed for all FoundationOne®Liquid samples and will only be reported if MSI-High is determined.

Assay specifications are based on samples meeting a minimum coverage threshold (>85% of targeted regions must have >2500x redundant coverage). Specimens with higher input mass typically obtain higher coverage and have higher sensitivity for low-frequency alterations.

For additional information specific to the performance of this specimen, please contact Foundation Medicine, Inc. at 1-888-988-3639.

ABOUT FOUNDATIONONE® LIQUID

FoundationOne Liquid was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid has not been cleared or approved by the United States Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. FoundationOne Liquid may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.

DIAGNOSTIC SIGNIFICANCE

FoundationOne Liquid identifies alterations to select cancer-associated genes or portions of genes (biomarkers).

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls. The threshold used in FoundationOne Liquid for identifying a copy number amplification is five (5) for ERBB2 and six (6) for all other genes. For copy number amplifications, the equivocal status may be applied to calls in samples with calculated tumor fraction <30% but above the noise threshold. In addition, copy number amplifications in genes with three (3) baited exons are also marked as equivocal.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

RANKING OF ALTERATIONS AND THERAPIES

Biomarker Findings

Appear at the top of the report, but are not ranked higher than Genomic Findings.

Genomic Findings

Therapies with Clinical Benefit In Patient's Tumor Type → Therapies with Clinical Benefit in Other Tumor Type → Clinical Trial Options → No Known Options (If multiple findings exist within any of these categories, the results are listed alphabetically by gene name.)

Therapies

Sensitizing therapies → Resistant Therapies. (If multiple therapies exist within any of these categories, they are listed in alphabetical order.)

Clinical Trials

Pediatric trial qualification → Geographical Proximity → Later trial phase.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test, or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid is performed using cell-free DNA, and as such germline events may not be reported. The following target typically has low coverage resulting in a reduction in sensitivity: *TP53* exon 1 and *PDGFRA* exon 12.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

1. Michels J, Vitale I, Saparbaev M, et al. (2014) Predictive biomarkers for cancer therapy with PARP inhibitors. *Oncogene* ePub Jul 2014
2. Weston VJ, Oldreive CE, Skowronska A, et al. (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. *Blood* ePub Nov 2010
3. Williamson CT, Muzik H, Turhan AG, et al. (2010) ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. *Mol. Cancer Ther.* ePub Feb 2010
4. Gilardini Montani MS, Prodosmo A, Stagni V, et al. (2013) ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. *J. Exp. Clin. Cancer Res.* ePub Nov 2013
5. Bryant HE, Helleday T (2006) Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. *Nucleic Acids Res.* ePub 2006
6. Ihnen M, zu Eulenburg C, Kolarova T, et al. (2013) Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. *Mol. Cancer Ther.* ePub Jun 2013
7. Williamson CT, Kubota E, Hamill JD, et al. (2012) Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. *EMBO Mol Med* ePub Jun 2012
8. Kubota E, Williamson CT, Ye R, et al. (2014) Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. *Cell Cycle* ePub 2014
9. Huehls AM, Wagner JM, Huntoon CJ, et al. (2012) Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination. *Mol. Pharmacol.* ePub Oct 2012
10. Mateo J, Carreira S, Sandhu S, et al. (2015) DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *N. Engl. J. Med.* ePub Oct 2015
11. Bang YJ, Im SA, Lee KW, et al. (2015) Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. *J. Clin. Oncol.* ePub Nov 2015
12. Riabinska A, Daheim M, Herter-Sprie GS, et al. (2013) Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. *Sci Transl Med* ePub Jun 2013
13. (2014) Comprehensive molecular profiling of lung adenocarcinoma. *Nature* ePub Jul 2014
14. Ding L, Getz G, Wheeler DA, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* ePub Oct 2008
15. Imielinski M, Berger AH, Hammerman PS, et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* ePub Sep 2012
16. (2012) Comprehensive genomic characterization of squamous cell lung cancers. *Nature* ePub Sep 2012
17. Hu S, Qu Y, Xu X, et al. (2013) Nuclear survivin and its relationship to DNA damage repair genes in non-small cell lung cancer investigated using tissue array. *PLoS ONE* ePub 2013
18. Pierceall WE, Olausson KA, Rousseau V, et al. (2012) Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. *Ann. Oncol.* ePub Sep 2012
19. Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. *Nat. Rev. Mol. Cell Biol.* ePub Apr 2013
20. Cremona CA, Behrens A (2014) ATM signalling and cancer. *Oncogene* ePub Jun 2014
21. Shaw RJ, Bardeesy N, Manning BD, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. *Cancer Cell* 6 (1):91-9
22. Ji H, Ramsey MR, Hayes DN, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. *Nature* ePub Aug 2007
23. Contreras CM, Gurumurthy S, Haynie JM, et al. (2008) Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. *Cancer Res.* ePub Feb 2008
24. Gurumurthy S, Hezel AF, Sahin E, et al. (2008) LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. *Cancer Res.* ePub Jan 2008
25. Shackelford DB, Vasquez DS, Corbeil J, et al. (2009) mTOR and HIF-1 α -mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. *Proc. Natl. Acad. Sci. U.S.A.* ePub Jul 2009
26. Baselga J, Campone M, Piccart M, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N. Engl. J. Med.* ePub Feb 2012
27. Hudes G, Carducci M, Tomczak P, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N. Engl. J. Med.* ePub May 2007
28. Fury MG, Sherman E, Haque S, et al. (2012) A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. *Cancer Chemother. Pharmacol.* ePub Mar 2012
29. Moroney J, Fu S, Moulder S, et al. (2012) Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. *Clin. Cancer Res.* 18 (20):5796-805
30. Klumpen HJ, Queiroz KC, Spek CA, et al. (2011) mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. *J. Clin. Oncol.* ePub Feb 2011
31. Carretero J, Shimamura T, Rikova K, et al. (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. *Cancer Cell* ePub Jun 2010
32. Koivunen JP, Kim J, Lee J, et al. (2008) Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. *Br. J. Cancer* ePub Jul 2008
33. An SJ, Chen ZH, Su J, et al. (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. *PLoS ONE* ePub 2012
34. Liu Y, Marks K, Cowley GS, et al. (2013) Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. *Cancer Discov* ePub Aug 2013
35. Gao B, Sun Y, Zhang J, et al. (2010) Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. *J Thorac Oncol* ePub Aug 2010
36. Bonanno L, De Paoli A, Zulato E, et al. (2017) LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. *Clin. Cancer Res.* 23 (13):3316-3324
37. Ollila S, Mäkelä TP (2011) The tumor suppressor kinase LKB1: lessons from mouse models. *J Mol Cell Biol* ePub Dec 2011
38. Qiu W, Schönleben F, Thaker HM, et al. (2006) A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma. *Oncogene* 25 (20):2937-42
39. Mehenni H, Gehrig C, Nezu J, et al. (1998) Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. *Am. J. Hum. Genet.* 63 (6):1641-50
40. Karuman P, Gozani O, Odze RD, et al. (2001) The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. *Mol. Cell* 7 (6):1307-19
41. Baas AF, Boudeau J, Sapkota GP, et al. (2003) Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. *EMBO J.* 22 (12):3062-72
42. Zeng PY, Berger SL (2006) LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. *Cancer Res.* 66 (22):10701-8
43. Boudeau J, Scott JW, Resta N, et al. (2004) Analysis of the LKB1-STRAD-MO25 complex. *J. Cell. Sci.* 117 (Pt 26):6365-75
44. Scott KD, Nath-Sain S, Agnew MD, et al. (2007) LKB1 catalytically deficient mutants enhance cyclin D1 expression. *Cancer Res.* 67 (12):5622-7
45. Xie Z, Dong Y, Zhang J, et al. (2009) Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. *Mol. Cell. Biol.* ePub Jul 2009
46. Boudeau J, Kieloch A, Alessi DR, et al. (2003) Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients. *Hum. Mutat.* ePub Feb 2003
47. Forcet C, Etienne-Manneville S, Gaude H, et al. (2005) Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. *Hum. Mol. Genet.* 14 (10):1283-92
48. Zhang L, Wang JC, Hou L, et al. (2015) Functional Role of Histidine in the Conserved His-x-Asp Motif in the Catalytic Core of Protein Kinases. *Sci Rep* ePub May 2015
49. Berger AH, Brooks AN, Wu X, et al. (2016) High-throughput Phenotyping of Lung Cancer Somatic Mutations. *Cancer Cell* ePub 08 2016
50. Amos CI, Keitheri-Cheteri MB, Sabripour M, et al. (2004) Genotype-phenotype correlations in Peutz-Jeghers syndrome. *J. Med. Genet.* ePub May 2004

51. Hearle N, Schumacher V, Menko FH, et al. (2006) Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin. Cancer Res.* 12 (10):3209-15
52. van der Groep P, van der Wall E, van Diest PJ (2011) Pathology of hereditary breast cancer. *Cell Oncol (Dordr)* ePub Apr 2011
53. Hezel AF, Gurumurthy S, Granot Z, et al. (2008) Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. *Mol. Cell. Biol.* ePub Apr 2008
54. Moreira et al., 2015; ASCO Abstract 315
55. Donovan LE, Arnal AV, Wang SH, et al. (2016) Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. *CNS Oncol* ePub Oct 2016
56. Soria JC, Shepherd FA, Douillard JY, et al. (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. *Ann. Oncol.* ePub Oct 2009
57. Khuri et al., 2011; ASCO Abstract e13601
58. Eberhardt WE, Mitchell P, Schiller JH, et al. (2014) Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naïve, advanced non-small cell lung cancer. *Invest New Drugs* ePub Feb 2014
59. Papadimitrakopoulou VA, Soria JC, Jappe A, et al. (2012) Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. *J Thorac Oncol* ePub Oct 2012
60. Besse B, Leigh N, Bennouna J, et al. (2014) Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. *Ann. Oncol.* ePub Feb 2014
61. Toffalorio F, Spitaleri G, Catania C, et al. (2014) Phase II study of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. *Oncologist* ePub Apr 2014
62. Tolcher AW, Bendell JC, Papadopoulos KP, et al. (2015) A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. *Ann. Oncol.* ePub Jan 2015
63. Olson D, Bhalla S, Yang X, et al. (2016) Novel Use of Targeted Therapy via PARP-Inhibition in a Rare Form of Papillary Renal Cell Carcinoma: A Case Report and Literature Review. *Clin Genitourin Cancer* ePub 08 2016
64. Sandhu SK, Schelman WR, Wilding G, et al. (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. *Lancet Oncol.* ePub Aug 2013
65. Campelo et al., 2018; ASCO Abstract 9012
66. Swisher EM, Lin KK, Oza AM, et al. (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncol.* ePub Jan 2017
67. Shapira-Frommer et al., 2015; ASCO Abstract 5513
68. Drew Y, Ledermann J, Hall G, et al. (2016) Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. *Br. J. Cancer* ePub Mar 2016
69. Kristeleit et al., 2014; ASCO Abstract 2573
70. Domcheck et al., 2016; ASCO Abstract 4110
71. Plummer R, Lorigan P, Steven N, et al. (2013) A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AGO14699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentialiation. *Cancer Chemother. Pharmacol.* ePub May 2013
72. Plummer R, Jones C, Middleton M, et al. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AGO14699, in combination with temozolomide in patients with advanced solid tumors. *Clin. Cancer Res.* 14 (23):7917-23
73. Wilson RH, Evans TJ, Middleton MR, et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. *Br. J. Cancer* ePub Mar 2017
74. Reungwetwattana T, Molina JR, Mandrekar SJ, et al. (2012) Brief report: a phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCTCG study. *J Thorac Oncol* ePub May 2012
75. Waqar SN, Robinson C, Bradley J, et al. (2014) A phase I study of temsirolimus and thoracic radiation in non-small-cell lung cancer. *Clin Lung Cancer* ePub Mar 2014